Abstract
In order to improve water solubility of a lipophilic drug, tacrolimus (FK506), two prodrugs (FK506-G or FK506-S) such as FK506-M32-LS-G (FK506-G) and FK506-M32-LS-SL (FK506-S) were synthesized. Two prodrugs (FK506-G or FK506-S), including FK506, were characterized by differential scanning calorimetry (DSC), X-ray diffractometry (XRD), scanning electron microscopy (SEM), enzymatic kinetics, and cytotoxicity. A phase solubility test was conducted in distilled water, and the solubility of two prodrugs (FK506-G or FK506-S) was measured in various pH values for pH solubility profiles. Most interesting was that FK506-S showed the highest solubility, 866 μg/mL in water. In vitro enzymatic kinetics of two prodrugs (FK506-G or FK506-S) in human plasma was evaluated by measuring the decrease of FK506-G or FK506-S as well as the increase of FK506 by HPLC, and FK506-G or FK506-S was metabolized in 1 h in human plasma. Two prodrugs (FK506-G or FK506-S) including FK506 showed an IC50 of 336.6 μg/mL for FK506, 337.9 μg/mL for FK506-G, or 480.1 μg/mL for FK506-S against a conjunctive cell line, Clone 1-5c-4 cells. Taken together, FK506-S could be the most optimal prodrug for aqueous preparations based on preformulation data.
Original language | English |
---|---|
Pages (from-to) | 1313-1319 |
Number of pages | 7 |
Journal | Bulletin of the Korean Chemical Society |
Volume | 37 |
Issue number | 8 |
DOIs | |
Publication status | Published - 2016 Aug 1 |
Bibliographical note
Funding Information:This research was supported by the Regional Industry Technology Development Program (70004763), through Daejeon Technopark funded by the Ministry of Knowledge Economy, and the Priority Research Centers Program (2009-0093815), through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology.
Publisher Copyright:
© 2016 Korean Chemical Society & Wiley-VCH Verlag GmbH & Co. KGaA.
All Science Journal Classification (ASJC) codes
- Chemistry(all)